Semaglutide in the Real World: Bridging Effectiveness and Clinical Feasibility Through Flexible Dose Titration
*Corresponding Author:Received Date: Mar 10, 2026 / Published Date: Apr 13, 2026
Citation: Pampanelli S. (2026) Semaglutide in the Real World: Bridging Effectiveness and Clinical Feasibility through Flexible Dose Titration. J Obes Weight Loss Ther S10:001.DOI: 10.4172/2165-7904.S10-001
Copyright: © 2026 Pampanelli S. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Semaglutide 2.4 mg, approved for chronic weight management, has generated a rapidly expanding body of Real World Evidence (RWE) that complements randomized trial data. This mini review synthesizes key observational findings (2023-2025) on effectiveness, dose titration patterns, and treatment persistence/discontinuation, with particular emphasis on practical implications for Italian care pathways. Large cohorts and registry/patient support program datasets report mean weight loss trajectories of approximately -13.4% at 6 months, -17.6% at 12 months, and ~-20% at 18-24 months among patients who remain on treatment and contribute follow up weight measures; the proportion achieving ≥ 20% weight loss increases over time. In parallel, real world dose escalation frequently diverges from the labeled schedule (dose increases every 4 weeks up to 2.4 mg): Only a minority of patients follow the standard titration scheme, whereas slower and intermittently interrupted patterns are common. Flexible, tolerability guided titration-documented in the FLEX SEMA study-appears to reduce early discontinuation while maintaining outcomes comparable to standard escalation despite a submaximal mean dose (~1.6 mg). Persistently recurring challenges include suboptimal persistence (with discontinuation rates up to ~52% at 12 months in some settings), early Gastrointestinal (GI) tolerability barriers, access constraints, and intermittent supply limitations. Collectively, RWE confirms substantial effectiveness but underscores the need for pragmatic implementation strategies-personalized titration to the maximum tolerated dose, intensified support during the first 3-6 months, sustainable access pathways, and systematic monitoring-to translate pharmacological efficacy into population level benefit.
